Literature DB >> 3785792

Rarity of cesarean delivery in cases of juvenile-onset respiratory papillomatosis.

K Shah, H Kashima, B F Polk, F Shah, H Abbey, A Abramson.   

Abstract

Papillomas of the respiratory and genital tracts are caused by the same papillomavirus genotypes, and mothers of children with respiratory papillomatosis often have a history of genital warts. Only one of 109 cases reviewed gave a history of birth by cesarean section, whereas ten cesarean deliveries would have been the expected number for this group on the basis of national rates. The single case was delivered by elective cesarean section before the rupture of the membranes, and the child developed respiratory papillomatosis in the first year of life. These findings suggest that in juvenile-onset disease, the transmission of infection from mother to child occurs most often during passage through an infected birth canal, but that intrauterine infection of the fetus is also possible. Papillomavirus infection of the female genital tract is common, but respiratory papillomatosis is rare. On the basis of crude estimates of annual number of children born to infected mothers and of new cases of juvenile-onset disease, the risk of developing disease for a child born to an infected mother was calculated to be one in several hundred exposures.

Entities:  

Mesh:

Year:  1986        PMID: 3785792

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  18 in total

1.  Homozygous NLRP1 gain-of-function mutation in siblings with a syndromic form of recurrent respiratory papillomatosis.

Authors:  Scott B Drutman; Filomeen Haerynck; Franklin L Zhong; David Hum; Nicholas J Hernandez; Serkan Belkaya; Franck Rapaport; Sarah Jill de Jong; David Creytens; Simon J Tavernier; Katrien Bonte; Sofie De Schepper; Jutte van der Werff Ten Bosch; Lazaro Lorenzo-Diaz; Andy Wullaert; Xavier Bossuyt; Gérard Orth; Vincent R Bonagura; Vivien Béziat; Laurent Abel; Emmanuelle Jouanguy; Bruno Reversade; Jean-Laurent Casanova
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-04       Impact factor: 11.205

2.  Novel human papilloma virus (HPV) genotypes in children with recurrent respiratory papillomatosis.

Authors:  Ioannis N Mammas; George Sourvinos; Elena Vakonaki; Panagiota Giamarelou; Catherine Michael; Demetrios A Spandidos
Journal:  Eur J Pediatr       Date:  2010-03-07       Impact factor: 3.183

Review 3.  5-FU for genital warts in non-immunocompromised individuals.

Authors:  Claudio S Batista; Alvaro N Atallah; Humberto Saconato; Edina Mk da Silva
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

4.  Recurrent respiratory papillomatosis causing chronic stridor and delayed speech in an 18-month-old boy.

Authors:  Adel Alharbi; Derek Drummond; Alfredo Pinto; Valerie Kirk
Journal:  Can Respir J       Date:  2006-10       Impact factor: 2.409

5.  Recurrent respiratory papillomatosis with pulmonary cystic disease in a child, following maternal genital warts.

Authors:  R T Sadikot; A C Andrew; J D Wilson; A G Arnold
Journal:  Genitourin Med       Date:  1997-02

Review 6.  A possible role for human papillomaviruses in head and neck cancer.

Authors:  B M Steinberg; T P DiLorenzo
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

Review 7.  Sexually transmitted diseases in sexually abused children: medical and legal implications.

Authors:  M R Hammerschlag
Journal:  Sex Transm Infect       Date:  1998-06       Impact factor: 3.519

Review 8.  Pathogenesis of genital HPV infection.

Authors:  A Schneider
Journal:  Genitourin Med       Date:  1993-06

9.  Multicenter initiative seeking critical genes in respiratory papillomatosis.

Authors:  Farrel J Buchinsky; Craig S Derkay; Suzanne M Leal; Joseph Donfack; Garth D Ehrlich; J Christopher Post
Journal:  Laryngoscope       Date:  2004-02       Impact factor: 3.325

Review 10.  Is administration of the HPV vaccine during pregnancy feasible in the future?

Authors:  Abbey B Berenson; Pooja R Patel; Alan D Barrett
Journal:  Expert Rev Vaccines       Date:  2013-11-28       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.